Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Oncologist
    April 2024
  1. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
    Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Oncologist. 2024;29:e498-e506.
    >> Share

  2. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
    Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
    Oncologist. 2024;29:e561-e569.
    >> Share

  3. ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al
    Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
    Oncologist. 2024 Apr 1:oyae050. doi: 10.1093.
    >> Share

    March 2024
  4. XU Y, Ji H, Zhang Y, Xiong L, et al
    Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
    >> Share

  5. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
    >> Share

  6. XU Y, Wen N, Haddad RI, Sonis ST, et al
    Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
    Oncologist. 2024;29:e382-e391.
    >> Share

    February 2024
  7. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    >> Share

  8. BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al
    Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
    Oncologist. 2024 Feb 20:oyad342. doi: 10.1093.
    >> Share

    January 2024
  9. KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al
    Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Oncologist. 2024 Jan 18:oyae001. doi: 10.1093.
    >> Share

  10. GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al
    Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist. 2024 Jan 11:oyad335. doi: 10.1093.
    >> Share

  11. WANG H, Fan Z, Yang X, Wu Q, et al
    Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
    Oncologist. 2024 Jan 10:oyad339. doi: 10.1093.
    >> Share

  12. BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al
    Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Oncologist. 2024;29:e118-e130.
    >> Share

  13. HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al
    Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Oncologist. 2024;29:e108-e117.
    >> Share

  14. JORDAN J, Maki RG
    The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.
    Oncologist. 2024;29:67-74.
    >> Share

    November 2023

  15. Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Nov 24:oyad316. doi: 10.1093.
    >> Share

  16. STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al
    Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Oncologist. 2023;28:e981-e994.
    >> Share

    October 2023
  17. HU X, Melson JW, Pan SS, Salei YV, et al
    Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer.
    Oncologist. 2023 Oct 5:oyad272. doi: 10.1093.
    >> Share

  18. SILVERSTEIN J, Wright F, Wang M, Young A, et al
    Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
    Oncologist. 2023;28:e950-e959.
    >> Share

    September 2023
  19. SHANG X, Zhang C, Kong R, Zhao C, et al
    Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine Learning.
    Oncologist. 2023 Sep 14:oyad261. doi: 10.1093.
    >> Share

  20. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
    Oncologist. 2023 Sep 5:oyad245. doi: 10.1093.
    >> Share

    August 2023
  21. ELKRIEF A, Riccuiti B, Alessi JV, Fei T, et al
    Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Aug 17:oyad197. doi: 10.1093.
    >> Share

  22. GENTZLER RD, Villaruz LC, Rhee JC, Horton B, et al
    Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
    Oncologist. 2023 Aug 9:oyad221. doi: 10.1093.
    >> Share

  23. HUNT AL, Nutcharoen A, Randall J, Papazian A, et al
    Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
    Oncologist. 2023;28:730-736.
    >> Share

  24. FARHA N, Faisal MS, Allende DS, Sleiman J, et al
    Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
    Oncologist. 2023;28:706-713.
    >> Share

    July 2023
  25. SULLIVAN HW, O'Donoghue AC, Boudewyns V, Paquin RS, et al
    Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.
    Oncologist. 2023;28:e542-e553.
    >> Share

  26. WEI Y, Zheng L, Yang X, Luo Y, et al
    Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.
    Oncologist. 2023 Jul 3:oyad193. doi: 10.1093.
    >> Share

    June 2023
  27. GENTZLER RD, Mohindra NA, Jalal SI, Reckamp KL, et al
    Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
    Oncologist. 2023 Jun 30:oyad180. doi: 10.1093.
    >> Share

  28. DUBE-PELLETIER M, Labbe C, Cote J, Pelletier-St-Pierre AA, et al
    Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2023 Jun 26:oyad182. doi: 10.1093.
    >> Share

  29. SMYTH EN, John J, Tiu RV, Willard MD, et al
    Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.
    Oncologist. 2023 Jun 26:oyad170. doi: 10.1093.
    >> Share

  30. JOHN AO, Ramnath N
    Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    Oncologist. 2023 Jun 20:oyad125. doi: 10.1093.
    >> Share

  31. MOORE AM, Nooruddin Z, Reveles KR, Koeller JM, et al
    Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.
    Oncologist. 2023 Jun 19:oyad172. doi: 10.1093.
    >> Share

  32. BAIJAL S, Crosbie P, Fenemore J, Desai K, et al
    Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.
    Oncologist. 2023 Jun 13:oyad134. doi: 10.1093.
    >> Share

  33. PRUIS MA, Krebs MG, Plummer R, De Vos F, et al
    A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
    Oncologist. 2023 Jun 1:oyad146. doi: 10.1093.
    >> Share

    May 2023
  34. ALTAN M, Soto F, Zhong LL, Akhmedzhanov FO, et al
    Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
    Oncologist. 2023 May 8:oyad118. doi: 10.1093.
    >> Share

  35. STENZINGER A, Cuffel B, Paracha N, Vail E, et al
    Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Oncologist. 2023;28:e242-e253.
    >> Share

  36. MATHIAS K, Rouhani S, Olson D, Bass AR, et al
    Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Oncologist. 2023;28:440-448.
    >> Share

  37. JOHNSON ML, Patel MR, Aljumaily R, Jones SF, et al
    A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
    Oncologist. 2023 May 2:oyad029. doi: 10.1093.
    >> Share

    April 2023
  38. WANG C, Zhao K, Hu S, Dong W, et al
    Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Oncologist. 2023 Apr 28:oyad111. doi: 10.1093.
    >> Share

  39. AGGARWAL C, Maity AP, Bauml JM, Long Q, et al
    A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Apr 26:oyad106. doi: 10.1093.
    >> Share

  40. TANIMURA K, Uchino J, Kimura H, Hiranuma O, et al
    Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
    Oncologist. 2023 Apr 13:oyad013. doi: 10.1093.
    >> Share

  41. HERZBERG BO, Manji GA
    KRAS: Druggable at Last.
    Oncologist. 2023;28:283-286.
    >> Share

  42. DANZIGER N, Sokol ES, Graf RP, Hiemenz MC, et al
    Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Oncologist. 2023;28:319-326.
    >> Share

  43. ICHT O, Leader A, Batat E, Yosef L, et al
    Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Oncologist. 2023 Apr 4:oyad061. doi: 10.1093.
    >> Share

    March 2023
  44. CHEN Y, Yu J, Meng X
    Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
    Oncologist. 2023 Mar 18:oyad066. doi: 10.1093.
    >> Share

  45. LI LX, Cappuzzo F, Matos I, Socinski MA, et al
    Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
    Oncologist. 2023 Mar 11:oyad043. doi: 10.1093.
    >> Share

  46. ZHANG J, Johnson M, Barve M, Bazhenova L, et al
    Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
    Oncologist. 2023 Mar 9:oyad051. doi: 10.1093.
    >> Share

    February 2023
  47. NOVELLO S, Califano R, Reinmuth N, Tamma A, et al
    RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Oncologist. 2023 Feb 23:oyac264. doi: 10.1093.
    >> Share


  48. Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2023 Feb 9:oyad018. doi: 10.1093.
    >> Share

    December 2022
  49. BARLESI F, Isambert N, Felip E, Cho BC, et al
    Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Oncologist. 2022 Dec 26:oyac253. doi: 10.1093.
    >> Share

  50. WOODFORD K, Koo K, Reynolds J, Stirling RG, et al
    Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.
    Oncologist. 2022 Dec 20:oyac246. doi: 10.1093.
    >> Share

    November 2022
  51. FRANK AJ, Dagogo-Jack I, Dobre IA, Tait S, et al
    Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2022 Nov 25:oyac226. doi: 10.1093.
    >> Share

  52. CHIHARA Y, Takeda T, Goto Y, Nakamura Y, et al
    A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Oncologist. 2022;27:903-e834.
    >> Share

  53. YAO J, Bergsland E, Aggarwal R, Aparicio A, et al
    DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Oncologist. 2022;27:940-951.
    >> Share

    October 2022

  54. Expression of Concern: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2022 Oct 31. pii: 6782256. doi: 10.1093.
    >> Share

  55. MOHAMED L, Manjrekar S, Ng DP, Walsh A, et al
    The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.
    Oncologist. 2022;27:849-856.
    >> Share

    September 2022
  56. ALVES PINTO I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM, et al
    EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Oncologist. 2022 Sep 13. pii: 6696863. doi: 10.1093.
    >> Share

  57. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
    Oncologist. 2022 Sep 6. pii: 6693237. doi: 10.1093.
    >> Share

  58. FUJIWARA Y, Takahashi Y, Okada M, Kishimoto T, et al
    Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Oncologist. 2022;27:e703-e722.
    >> Share

    August 2022
  59. HSU ML, Murray JC, Psoter KJ, Zhang J, et al
    Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
    Oncologist. 2022 Aug 16. pii: 6668266. doi: 10.1093.
    >> Share


  60. Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Aug 6. pii: 6657714. doi: 10.1093.
    >> Share

  61. OFFIN M, Rusch VW, Rimner A, Adusumilli PS, et al
    Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
    Oncologist. 2022;27:610-614.
    >> Share

    July 2022
  62. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    >> Share

  63. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    >> Share

  64. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    >> Share

    June 2022
  65. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
    Oncologist. 2022 Jun 27. pii: 6618634. doi: 10.1093.
    >> Share

  66. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    >> Share

  67. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    >> Share

    May 2022
  68. HUANG RSP, Harries L, Decker B, Hiemenz MC, et al
    Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Oncologist. 2022 May 22. pii: 6590419. doi: 10.1093.
    >> Share

  69. MURUGESAN K, Jin DX, Comment LA, Fabrizio D, et al
    Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Oncologist. 2022 May 22. pii: 6590420. doi: 10.1093.
    >> Share

  70. ISAWA T, Toi Y, Sugawara S, Taguri M, et al
    Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:e410-e419.
    >> Share

    April 2022
  71. PASELLO G, Lorenzi M, Calvetti L, Oliani C, et al
    Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Apr 16. pii: 6569250. doi: 10.1093.
    >> Share

  72. POPAT S, Hsia TC, Hung JY, Jung HA, et al
    Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Oncologist. 2022;27:255-265.
    >> Share

    March 2022
  73. LEMMON CA, Zabor EC, Pennell NA
    Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Oncologist. 2022 Mar 14. pii: 6548144. doi: 10.1093.
    >> Share

  74. JIAN H, Wang K, Cheng Y, Ding L, et al
    Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2022;27:163-e213.
    >> Share

  75. TAN R, Yun C, Seetasith A, Sheinson D, et al
    Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
    Oncologist. 2022;27:236-243.
    >> Share

  76. WELLS JC, Sidhu A, Ding K, Smoragiewicz M, et al
    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
    Oncologist. 2022;27:e286-e293.
    >> Share

  77. STURGILL EG, Misch A, Jones CC, Luckett D, et al
    Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Oncologist. 2022;27:175-182.
    >> Share

  78. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2022;27:87-e115.
    >> Share

  79. PENG W, Cao L, Chen L, Lin G, et al
    Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Oncologist. 2022;27:e116-e125.
    >> Share

  80. PAVAN A, Ferro A, Fortarezza F, Schiavon M, et al
    Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
    Oncologist. 2022;27:e199-e202.
    >> Share

    February 2022
  81. MORABITO A, Manzo A, Montanino A, Rachiglio AM, et al
    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Oncologist. 2022;27:7-12.
    >> Share

  82. MOSKOVITZ M, Dudnik E, Shamai S, Rotenberg Y, et al
    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Oncologist. 2022;27:e76-e84.
    >> Share

  83. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
    Oncologist. 2022;27:67-78.
    >> Share

    December 2021
  84. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    >> Share

  85. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    >> Share

  86. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    >> Share

    November 2021
  87. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    >> Share

  88. AMELOT A
    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.
    >> Share

  89. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    >> Share

    October 2021
  90. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    >> Share

  91. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    >> Share

  92. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    >> Share

    September 2021
  93. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    >> Share

  94. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    >> Share

  95. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    >> Share

    August 2021
  96. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    >> Share

  97. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    >> Share

  98. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    >> Share

    July 2021
  99. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    >> Share

  100. LEE Y, Cho Y, Park EY, Park SY, et al
    One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
    Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
    >> Share

  101. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
    >> Share

  102. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
    Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
    >> Share

  103. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    >> Share

  104. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    >> Share

    June 2021
  105. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
    Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
    Oncologist. 2021;26:e1085-e1086.
    >> Share

  106. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist. 2021;26:523-532.
    >> Share

    May 2021
  107. ALKREKSHI A, Tamaskar I
    Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Oncologist. 2021;26:e827-e830.
    >> Share

  108. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Oncologist. 2021;26:356-361.
    >> Share

    April 2021
  109. KRUG K, Bossert J, Deis N, Krisam J, et al
    Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
    Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
    >> Share

  110. PERAVALI M, Ahn J, Chen K, Rao S, et al
    Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
    Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
    >> Share

  111. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    >> Share

  112. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.
    >> Share

  113. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    >> Share

  114. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    >> Share

    March 2021
  115. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    >> Share

  116. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    >> Share

    January 2021
  117. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    >> Share

  118. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016